Skip to main content
Premium Trial:

Request an Annual Quote

RBM to Develop, Sell Schizophrenia Biomarker Test with Psynova Neurotech

NEW YORK (GenomeWeb News) – Rules-Based Medicine said today it will work with start-up drug firm Psynova Neurotech to develop and sell a biomarker-based blood test that could be used to help diagnose schizophrenia. 
The companies will work together to validate, seek regulatory approval for, and manufacture the schizophrenia test, which RBM will sell exclusively worldwide.
Psynova discovered the biomarkers the companies will test through a collaboration with the Cambridge Centre for Neuropsychiatric Research at the Institute of Biotechnology, Cambridge University. Those collaborators processed samples using RBM’s HumanMAP multiplex platform.
Current diagnosis of schizophrenia is highly subjective and time consuming, the company said, and the biomarker-based tests will help general practitioners and psychiatrists diagnose and treat patients early on, while their symptoms are mild.
Psynova Neurotech was founded by University of Cambridge researchers Sabine Bahn and Chris Lowe, and was funded by Porton Capital.
Financial terms of the agreement were not released.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.